What is causing the 5% surge in Zydus Life shares on Tuesday — Explained

In a separate filing late last night, Zydus said that the US FDA has accepted Sentynl’s New Drug Application (NDA) for CUTX-101, for filing and priority review.

Leave a Reply

Your email address will not be published. Required fields are marked *